CPT® Editorial Summary of Panel Actions October 2022

Please be aware that this action is a reflection of the discussion at the most recent virtual Panel meeting.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the [AMA Website](https://www.ama-assn.org). Addition of 1 Category I code (0044A) accepted by the CPT Editorial Panel. Code 0044A and all related references will be published in CPT 2024. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.

Updated effective date for codes 0124A, 0134A, 91312, and 91313.

Removal of FDA approval pending symbol (✓) from codes 91312 and 91313.

Updated code 0144A by adding “A” to the term “mRNA” in the code descriptor.

Updated Appendix Q table to revise the patient ages for codes 91304 and 91313.

Codes 0134A and 91313 for patient aged 18 years and older are effective August 31, 2022 and patient aged 12 years through 17 years will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

<table>
<thead>
<tr>
<th>Name</th>
<th>Code #</th>
<th>Description of Editorial Panel Action</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only</td>
<td>0044A</td>
<td><strong>Accepted addition</strong> of code 0044A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91304); <strong>accepted revision</strong> of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include code 0044A; and <strong>accepted revision</strong> of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
</tr>
</tbody>
</table>